ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0,00010
arrow_downward
-97,14%(-0,0034) 1G
29 Nis, 16:00:00 GMT-4 · USD
search
Tüm semboller
1G
5G
1A
6A
Yıl Başından Beri
1Y
5Y
MAKS
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoADAPY ile ilgili en önemli analizler oluşturuluyor...
Açık
$0,00
Yüksek
$0,01
Düşük
$0,00
Piy. değ.
13,52 B
Ort. hacim
281,50 B
İşlem Hacmi
17,46 B
52 haftalık en yüksek
$0,36
52 haftalık en düşük
$0,00
HBK
-$0,66
Beta
2,42
Tedavüldeki hisse senedi sayısı
265,05 Mn
Çalışan sayısı
506
Haberler
Web genelindeki kaynaklardan
Simply Wall Street
·
7 dakika önce
Ribbon Communications (RBBN) Returns To Quarterly Loss Challenging New Profitability Narrative
富途牛牛
·
25 dakika önce
Dow Jones Top Markets Headlines at 11 PM ET: Powell Won't Leave. The Fed Won't Cut. Warsh Will Have to Deal With Both. | ECB, ...
Investor's Business Daily
·
37 dakika önce
Tech Futures Rise On Titans' Results And CapEx Plans
Profil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR hakkında
Yapay zeka içeriklerinde hata olabilir. Daha fazla bilgi